Qiagen, Illumina to deliver NGS-based IVD kits

Create PDF

Oct. 9, 2019—Illumina and Qiagen announced a 15-year partnership intended to broaden the availability and use of NGS-based in vitro diagnostic kits, including companion diagnostics, for patient management.

The agreement grants Qiagen nonexclusive rights to develop and globally commercialize IVD kits to be used with Illumina’s MiSeq Dx and NextSeq 550Dx systems and includes rights for expansion of the partnership on future Illumina diagnostic systems. The companies are also exploring opportunities for Qiagen to develop and market companion diagnostics based on Illumina’s TruSight Oncology assays that enable comprehensive genomic profiling of tumor samples in immunotherapy.